These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 22887851)
41. [Erysipelas without fever or biologic inflammation during tocilizumab therapy]. Yéléhé-Okouma M; Henry J; Petitpain N; Schmutz JL; Gillet P Ann Dermatol Venereol; 2017; 144(6-7):434-437. PubMed ID: 28396064 [TBL] [Abstract][Full Text] [Related]
42. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Ribeiro AC; Laurindo IM; Guedes LK; Saad CG; Moraes JC; Silva CA; Bonfa E Arthritis Care Res (Hoboken); 2013 Mar; 65(3):476-80. PubMed ID: 22949223 [TBL] [Abstract][Full Text] [Related]
43. Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy. Hu W; Ding Y; Guan K; Zhang P; Su J; Zhang C; Li W; Lian C; Yang Q; Liu S; Li T Clin Rheumatol; 2024 Jun; 43(6):1845-1853. PubMed ID: 38696116 [TBL] [Abstract][Full Text] [Related]
44. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078 [TBL] [Abstract][Full Text] [Related]
45. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Navarro-Millán I; Singh JA; Curtis JR Clin Ther; 2012 Apr; 34(4):788-802.e3. PubMed ID: 22444783 [TBL] [Abstract][Full Text] [Related]
46. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Garnero P; Thompson E; Woodworth T; Smolen JS Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425 [TBL] [Abstract][Full Text] [Related]
47. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918 [TBL] [Abstract][Full Text] [Related]
48. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973 [TBL] [Abstract][Full Text] [Related]
49. Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis. Verhoeven MMA; Tekstra J; van Laar JM; Pethö-Schramm A; Borm MEA; Bijlsma JWJ; Jacobs JWG; Lafeber FPJG; Welsing PMJ J Rheumatol; 2021 Apr; 48(4):495-503. PubMed ID: 32739893 [TBL] [Abstract][Full Text] [Related]
50. Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. O'Mahony A; John MR; Cho H; Hashizume M; Choy EH J Transl Med; 2018 Jun; 16(1):156. PubMed ID: 29879987 [TBL] [Abstract][Full Text] [Related]
51. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. McLaughlin M; Östör A Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607 [TBL] [Abstract][Full Text] [Related]
52. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis. Kondo N; Fujisawa J; Endo N Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541 [TBL] [Abstract][Full Text] [Related]
53. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Gelinck LB; van der Bijl AE; Beyer WE; Visser LG; Huizinga TW; van Hogezand RA; Rimmelzwaan GF; Kroon FP Ann Rheum Dis; 2008 May; 67(5):713-6. PubMed ID: 17965123 [TBL] [Abstract][Full Text] [Related]
54. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061 [TBL] [Abstract][Full Text] [Related]
55. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Hua C; Barnetche T; Combe B; Morel J Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1016-26. PubMed ID: 24339395 [TBL] [Abstract][Full Text] [Related]
56. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T; Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782 [TBL] [Abstract][Full Text] [Related]
57. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL; Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894 [TBL] [Abstract][Full Text] [Related]
58. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571 [TBL] [Abstract][Full Text] [Related]
59. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; Hendriks L; Denissen NHAM; van Laar JM; Lafeber FPJG; Bijlsma JWJ Rheumatology (Oxford); 2017 Dec; 56(12):2179-2189. PubMed ID: 29029185 [TBL] [Abstract][Full Text] [Related]
60. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]